NASDAQ:AMRX Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis $19.61 -0.04 (-0.21%) As of 02:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amneal Pharmaceuticals Stock (NASDAQ:AMRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amneal Pharmaceuticals alerts:Sign Up Key Stats Today's Range$18.97▼$19.7250-Day Range$16.65▼$20.5052-Week Range$9.56▼$21.17Volume1.74 million shsAverage Volume2.23 million shsMarket Capitalization$6.26 billionP/E Ratio40.02Dividend YieldN/APrice Target$21.00Consensus RatingModerate Buy Company Overview Amneal Pharmaceuticals, Inc. is a global pharmaceutical company that develops, manufactures and markets a broad portfolio of generic and specialty medicines. The company focuses on complex and difficult-to-manufacture products, including injectables, biosimilars, ophthalmic medicines, respiratory treatments, oncology products, transdermal formulations and other dosage forms. Amneal also operates a specialty pharmaceutical business focused on branded products in areas such as central nervous system disorders, endocrinology and other therapeutic categories. Its portfolio has included treatments such as Rytary, a carbidopa and levodopa product for Parkinson’s disease, as well as products for thyroid disorders and other conditions. The company was formed in 2017 through the combination of Amneal Pharmaceuticals, founded by brothers Chirag Patel and Chintu Patel, and Impax Laboratories. Amneal is headquartered in Bridgewater, New Jersey, and maintains research, development and manufacturing operations in the United States and India. Its products are marketed in the United States and selected international markets. Chirag Patel and Chintu Patel have served as the company’s co-chief executive officers.AI Generated. May Contain Errors. Read More Amneal Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreAMRX MarketRank™: Amneal Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 271st out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingModerate Buy Consensus RatingAmneal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Amneal Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAmneal Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amneal Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth13.68% Earnings GrowthEarnings for Amneal Pharmaceuticals are expected to grow by 13.68% in the coming year, from $0.95 to $1.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amneal Pharmaceuticals is 40.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Amneal Pharmaceuticals is 40.02, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.65.Price to Earnings Growth RatioAmneal Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.27% of the float of Amneal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmneal Pharmaceuticals has a short interest ratio ("days to cover") of 6.64.Change versus previous monthShort interest in Amneal Pharmaceuticals has recently increased by 6.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmneal Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmneal Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.31 News SentimentAmneal Pharmaceuticals has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Amneal Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest9 people have searched for AMRX on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows5 people have added Amneal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amneal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,216,567.00 in company stock.Percentage Held by Insiders17.30% of the stock of Amneal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions31.82% of the stock of Amneal Pharmaceuticals is held by institutions.Read more about Amneal Pharmaceuticals' insider trading history. Receive AMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMRX Stock News HeadlinesAmneal to Report Third Quarter 2026 Results on November 3, 2026October 8 at 8:00 AM | globenewswire.comAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Cut to Strong Sell at Zacks ResearchOctober 8 at 6:12 AM | americanbankingnews.comFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises new questions about how protected everyday bank accounts and retirement savings really are.October 8 at 1:00 AM | Priority Gold (Ad)Amneal Pharmaceuticals (AMRX) Stock Gets Fair Value Bump After Analyst Backing For New LaunchesOctober 3, 2026 | finance.yahoo.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Rated "Moderate Buy" by Wall Street BrokeragesOctober 1, 2026 | americanbankingnews.comOppenheimer initiates coverage of Amneal Pharmaceuticals at outperformSeptember 24, 2026 | msn.comAmneal Pharmaceuticals' Biosimilars, Specialty Growth Reshape Earnings Profile, Oppenheimer SaysSeptember 23, 2026 | finance.yahoo.comAmneal: Even My Bull Case Barely Justifies $20/ShareSeptember 22, 2026 | seekingalpha.comSee More Headlines AMRX Stock Analysis - Frequently Asked Questions How have AMRX shares performed this year? Amneal Pharmaceuticals' stock was trading at $12.60 at the start of the year. Since then, AMRX stock has increased by 55.6% and is now trading at $19.6080. How were Amneal Pharmaceuticals' earnings last quarter? Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) issued its quarterly earnings data on Thursday, July, 30th. The company reported $0.30 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.06. The firm had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a negative trailing twelve-month return on equity of 584.46% and a net margin of 5.05%. Read the conference call transcript. Who are Amneal Pharmaceuticals' major shareholders? Top institutional investors of Amneal Pharmaceuticals include Congress Asset Management Co. (0.48%). Insiders that own company stock include Tushar Bhikhubhai Patel, Gautam Patel, Ted C Nark, Nikita Shah, John Kiely, Andrew S Boyer, Deborah M Autor and Jason B Daly. View institutional ownership trends. How do I buy shares of Amneal Pharmaceuticals? Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amneal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amneal Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), TotalEnergies (TTE), Voyager Therapeutics (VYGR), Broadcom (AVGO) and Waste Connections (WCN). Company Calendar Last Earnings7/30/2026Today10/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 AMRX's financial health is in the Green zone, according to TradeSmith. AMRX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AMRX Previous SymbolNASDAQ:AMRX CIK1723128 Webamneal.com Phone908-947-3120Fax908-947-3146Employees8,500Year Founded2002Price Target and Rating Average Price Target for Amneal Pharmaceuticals$21.00 High Price Target$27.00 Low Price Target$13.00 Potential Upside/Downside+6.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$0.49 Trailing P/E Ratio39.96 Forward P/E Ratio20.72 P/E Growth2.38Net Income$72.06 million Net Margins5.05% Pretax Margin6.45% Return on Equity-584.46% Return on Assets7.78% Debt Debt-to-Equity Ratio77.65 Current Ratio2.20 Quick Ratio1.44 Sales & Book Value Annual Sales$3.02 billion Price / Sales2.08 Cash Flow$1.51 per share Price / Cash Flow13.00 Book Value($0.23) per share Price / Book-85.57Miscellaneous Outstanding Shares319,350,000Free Float264,106,000Market Cap$6.28 billion OptionableOptionable Beta1.22 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:AMRX) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersNNVC Is Heading Into a Big MomentNanoViricides (NYSE American: NNVC) is moving NV-387 into a Phase II trial for Ebola in the Democratic Republi...Equiscreen | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredWall Street Legend: “Global Market Freeze Coming”Dr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehm...Weiss Ratings | SponsoredWhy The Biggest Names in AI Are Heading To The ArcticGoogle contracted over 12 GW of energy last year and just announced a 15 billion dollar AI infrastructure inve...The Tomorrow Investor | SponsoredFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises...Priority Gold | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRX Stock Alerts